seqirus.comGlobal Biotechnology Company | CSL

Global Selector Newsroom Partnering Contact We Are CSL We Are CSL Our Businesses and Products Vita: Original Stories Our Leadership Worldwide Locations Corporate Governance Our Businesses and Products CSL Behring CSL Seqirus CSL Vifor Corporate Governance Code of Responsible Business Practice Core Policies Vita means life. It’s also our platform for sharing the stories of biotech’s promise to patients and public health. Read the Stories CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section. Our Businesses and Products Patients & Public Health Patients & Public Health Rare & Serious Diseases Iron Deficiency Nephrology Vaccines Patient Support & Organizations Rare & Serious Diseases Immunodeficiency and Autoimmune Diseases Hereditary Bleeding Disorders Hereditary Angioedema Alpha 1 Antitrypsin Deficiency Iron Deficiency Iron Deficiency Patient Stories Nephrology Nephrology Patient Stories Vaccines Pandemic Response In-Licensing Antivenoms and Q fever Vaccine Patient Support & Organizations CSL Behring USA Support & Assistance Programs CSL Vifor Managed Access Programs LEAD Grants Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry. CSL Behring: Rare & Serious Diseases Derived from the expression ’securing health for all of us’, CSL Seqirus is one of the world’s largest influenza vaccine providers. CSL Seqirus: Vaccines R&D R&D R&D Capabilities Awards, Grants and Initiatives World-Class R&D Network Product Pipeline Clinical Studies at CSL Clinical Studies at CSL Current Clinical Trials Research Practices How to Participate Clinical Studies FAQs R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology. R&D Capabilities One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world. Awards, Grants and Initiatives Sustainability Sustainability Environment Social Sustainable Workforce Governance Data and Reporting Centre Environment Climate Resilience Energy and Emissions Waste, Water and Packaging Social Product Safety & Quality Innovation and R&D Access & Health Security Responsible & Resilient Supply Chain Sustainable Workforce Providing A Positive Working Environment Health, Safety & Wellbeing Diversity, Equity & Inclusion Governance Ethics & Transparency Data Protection & Privacy Stakeholder Engagement & Material Topics Data and Reporting Centre Annual Publications Policies Key Performance Data Summary As part of our broader sustainability strategy to build a more sustainable future, we’ve committed to a 40% reduction in absolute Scope 1 and 2 emissions by 2030. Learn About Our Targets Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy. Supporting Our Communities Careers Careers Diversity, Equity & Inclusion How CSL Supports Your Well-being Early Careers at CSL Early Careers at CSL Apprenticeships Internships at CSL Graduate Rotational Programs at CSL At CSL, Diversity, Equity, and Inclusion (DEI) is at the core of our mission and who we are. It fuels our innovation day in and day out. Read About Our DE&I Whether you are early in your college education or recently completed your degree, it’s never too soon to consider CSL for your Promising Future! Early Careers at CSL Investors CSL Back Search We Are CSL We Are CSL Our Businesses and Products Our Businesses and Products CSL Behring CSL Seqirus CSL Vifor Vita: Original Stories Our Leadership Worldwide Locations Corporate Governance Corporate Governance Code of Responsible Business Practice Core Policies Patients & Public Health Patients & Public Health Rare & Serious Diseases Rare & Serious Diseases Immunodeficiency and Autoimmune Diseases Hereditary Bleeding Disorders Hereditary Angioedema Alpha 1 Antitrypsin Deficiency Iron Deficiency Iron Deficiency Iron Deficiency Patient Stories Nephrology Nephrology Nephrology Patient Stories Vaccines Vaccines Pandemic Response In-Licensing Antivenoms and Q fever Vaccine Patient Support & Organizations Patient Support & Organizations CSL Behring USA Support & Assistance Programs CSL Vifor Managed Access Programs LEAD Grants R&D R&D R&D Capabilities Awards, Grants and Initiatives World-Class R&D Network Product Pipeline Clinical Studies at CSL Clinical Studies at CSL Current Clinical Trials Research Practices How to Participate Clinical Studies FAQs Sustainability Sustainability Environment Environment Climate Resilience Energy and Emissions Waste, Water and Packaging Social Social Product Safety & Quality Innovation and R&D Access & Health Security Responsible & Resilient Supply Chain Sustainable Workforce Sustainable Workforce Providing A Positive Working Environment Health, Safety & Wellbeing Diversity, Equity & Inclusion Governance Governance Ethics & Transparency Data Protection & Privacy Stakeholder Engagement & Material Topics Data and Reporting Centre Data and Reporting Centre Annual Publications Policies Key Performance Data Summary Careers Careers Diversity, Equity & Inclusion How CSL Supports Your Well-being Early Careers at CSL Early Careers at CSL Apprenticeships Internships at CSL Graduate Rotational Programs at CSL Investors Newsroom Partnering Contact Global Selector ) CSL Seqirus Pictured: CSL Seqirus employee in the lab in Massachusetts, USA CSL We Are CSL Our Businesses and Products CSL Seqirus Securing Health for All of Us Derived from the expression ’ securing health for all of us ’, CSL Seqirus has public health protection at its core. This reflects the promise of our parent company CSL, founded in 1916 to save lives and protect the health of people. Our first true test came with the Spanish Influenza Pandemic and we have been committed to the fight against influenza ever since. Influenza kills. But at CSL Seqirus, we believe it shouldn’t be that way. As the only vaccine company with a singular global focus on influenza, we work tirelessly on cutting-edge research, transformative technologies and the latest methods of production and distribution. Together with our partners we’re on the front line every day, protecting communities from seasonal influenza and global pandemic threats. Our vision is a world protected from influenza. Areas of Expertise Influenza Vaccines We are one of the world’s largest influenza vaccine companies with a singular global focus on influenza. Pictured: CSL Seqirus employee working in the lab in Liverpool, UK Learn More About Our Vaccines Pandemic Response Experts agree that there will be another influenza pandemic this century 1 . CSL Seqirus offers a portfolio of pandemic vaccines and services for rapid response. Learn More About Our Pandemic Response In-Licensing CSL Seqirus is the largest fully integrated commercialisation partner for vaccines and pharmaceuticals in Australia and New Zealand. Learn More About Our In-Licensing Programs Antivenoms and Q fever vaccine CSL Seqirus is the supplier of a unique range of antivenoms and Q fever vaccine for the Australian government. Learn More About These Programs Our Manufacturing Expertise CSL Seqirus operates state-of-the-art manufacturing facilities in three different continents and a globally integrated supply chain for the timely supply of influenza vaccine to customers around the world. Pictured: CSL Seqirus manufacturing employees in Holly Springs, NC, USA Learn More About Our Manufacturing Our Products As a global leader in influenza protection, CSL Seqirus has one of the broadest influenza vaccine portfolios in the world. Learn More About Our Products * World Health Organisation. Influenza (seasonal) Fact Sheet, November 2018. Available online: http://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal) (Accessed October 2020) ^de Boer, P. et al, A...